𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Is there a role for surgery in patients with “unresectable” cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate?

✍ Scribed by Courtney L Scaife; Kelly K Hunt; Shreyaskumar R Patel; Robert S Benjamin; Michael A Burgess; Lei L Chen; Jonathan Trent; A.Kevin Raymond; Janice N Cormier; Peter W.T Pisters; Raphael E Pollock; Barry W Feig

Book ID
116214594
Publisher
Elsevier Science
Year
2003
Tongue
English
Weight
49 KB
Volume
186
Category
Article
ISSN
0002-9610

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Expression of Bcl-2 in gastrointestinal
Expression of Bcl-2 in gastrointestinal stromal tumors : Correlation with progression-free survival in 81 patients treated with imatinib mesylate
✍ Dejka M. Steinert; Mauricio Oyarzo; Xuemei Wang; Haesun Choi; Peter F. Thall; L. 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 224 KB 👁 1 views

## Abstract ## BACKGROUND The natural history of gastrointestinal stromal tumor (GIST) has been revolutionized by imatinib mesylate (imatinib) therapy. Before imatinib, Bcl‐2 expression in GIST was associated with a worse prognosis or added no additional prognostic value. To the authors' knowledge